Evgen Pharma Share Discussion Threads

[moneymunch] 17/4/2021 15:40

Conflicts of interests!!!???? ;-)

James D Chalmers
@ProfJDChalmers
·
5h

Looking forward to speaking with experts on public health, education, social sciences, politics and others tonight

Escaping to a post-COVID world (sounds good right?)


10:19 am · 17 Apr 2021·Twitter Web App

James D Chalmers
@ProfJDChalmers

Researchers: we used (insert incredibly complex dataset) to test (complex hypothesis) using machine learning and (complex statistics).

Also Researchers: Sorry we didn't declare our conflicts of interests, those forms are really complicated

[muddy_40] 17/4/2021 14:40

I was listening to BBC world service on radio. They were talking about Covid deaths hitting over 3 million. And how bad it is in India with this new strain of covid which hits mainly the lungs. And the John Hopkins was mentioned. It never mentioned Sulforaphane or that

I think it goes to show how well John Hopkins is thought of worldwide. And we know they are in favour of our SFX1 compound.

Hopefully with a good bit of luck it is a big winner

[bumpa33] 17/4/2021 11:08

Yep, we had a pre covid world which has gone - the talk now is of a post covid world but that implies “after covid”. I don’t think, unfortunately, that we are going to be rid of this anytime soon. Look at the research out there and it’s pretty much telling us that for now, it’s here to stay.

[moneymunch] 17/4/2021 11:00

Lol Bumpa, who knows but this could be bigger than Bitcoin if efficacy is proven and correlates with John Hopkins stunning research, ie the pandemic is surging out of control across the globe with the fear that the current vaccines could be ineffective to the new and ever increasing variants, and so can you imagine, SFX-01 is administered to treat those with Covid-19 and ARDS etc, but SFX-01 is also administered to stop you getting Covid-19 etc...this could be well and truly massive if that turned out to be the case....the world population dropping an SFX-01 on a regular basis to ward off the lurgy...Gl ;-))))

[bumpa33] 17/4/2021 10:32

Yes, “pre-treated” is quite exciting. Meanwhile the wider mkt continues to ignore - I guess “understanding” cryptos or whatever is easier :)

[bumpa33] 17/4/2021 10:18

a bit to take in but really worth reading, history of human coronavirus, explanation of various animal models, the role of viral shedding, currently repurposed drugs etc etc.

Anti-virals will play a massive part in the battle against coronavirus - vaccines can’t do it all. It would seem from this paper that so far, the only repurposed drug to have (some, indeed any) efficacy remains Remdesivir.







Reposting this again because I haven’t seen anyone comment on what was summed up in the last paragraph (Conclusion)...



“We documented that SFN can inhibit the in vitro and in vivo replication of SARS-CoV-2 at pharmacologically and therapeutically achievable doses and can modulate the inflammatory response thereby decreasing the consequences of infection in the animal model when administered prior to infection. Given that SFN is orally bioavailable, commercially available, and has limited side-effects, our results suggest it could be a promising and easily scalable approach for the prevention and treatment of COVID-19 as well as other coronavirus infections.”

[moneymunch] 17/4/2021 10:06

Ps 102 patients recruited to SFX-01 Covid/ARDS trial as of 16th February 2021....14 days dosing and then 28 days observation takes the first 100 trial patients to the end of March and the likely start of Prof Chalmers preliminary efficacy assessment although some of the exploratory objectives could have been ongoing since the start of the trial, blood and cell analysis etc.....Gla ;-)

The trial will test the following hypothesis:

Treatment with SFX-01 in addition to standard care will be superior to placebo plus standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection).

.........................

Primary objective:

To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia. Outcome measure:7 point ordinal scale measured on Day 15.

Secondary Objectives:

Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19

Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm

Outcome measures:

Cumulative incidence of serious Adverse events (SAEs)

Discontinuation or temporary suspension of treatment

..............................

Exploratory objectives (All sites)

Biofire analysis of nasal swab or sputum sample

Subanalysis of outcomes according to the causative pathogen

Exploratory objectives (TAYSIDE ONLY)

Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells

Neutrophil functional studies in isolated cells

Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood

[moneymunch] 16/4/2021 18:48

The accumulation of cheap shares continues. Gla ;-)

[moneymunch] 16/4/2021 07:33

The market's awaiting Prof Chalmers preliminary efficacy assessment on SFX-01's Covid/ARDS patient trial, this will explode into life on positive data and there will be a mad dash for shares from new investors, and then Huw has multiple newsflow from the rest of the pipeline to report thereafter that could also add significant value.........Gla Holders.....Excitement building in anticipation of Prof Chalmers update that could be very close imho. ;-)

[amaretto1] 15/4/2021 17:22

It needs something ...SP is disastrous

[moneymunch] 15/4/2021 14:51

Well, we've got a raft of potential good news to look forward to this Q2 that could move the share price significantly UPwards, and every chance that Prof Chalmers preliminary efficacy assessment on SFX-01's Covid/ARDS patient trial will drop this month, where positive efficacy data could see the share price explode into life....Tick Tock.... Gla ;-)

[bumpa33] 14/4/2021 13:23

then your broker is looking in the wrong place (or not at all) mesquida - I have explained this before. I agree though, i don’t think this will move until we get news.

[on target] 14/4/2021 10:42

That's been the case since last year mesquida so not sure it's got anything to do with the placing. But we do know there are holders such as Griffiths selling down and a gang of spread-betters who can't seem to sit still.

[mesquida] 14/4/2021 10:22

Bumpa, i cannot even get a bid to sell 25k this morning. I am as bullish of the company's prospects as you are, but the reality is that this stock will not rise without an announcemnt, in the wake of the placing there are just too many shares in loose hands ( as always happens with FinnCap ).

[mesquida] 13/4/2021 20:51

Bumpa, are you telling me that there was no offer today ? Must admit that i did not check the offer today, but i did try a dummy sale this morning and found the stock was not at all well bid, not even in 50k if i remember correctly. If you found them well bid with little offered later on then this bodes well for tomorrow.

[moneymunch] 13/4/2021 15:54

The calm before the storm....news from Prof Chalmers on SFX-01's preliminary efficacy assessment for Covid/ARDS coming soon, and maybe in time for the following two Covid-19 presentation/discussions this month where Prof Chalmers is involved. Gla ;-)


Escaping to a post-Covid world. 17 April 2021

“However, it has also highlighted some of our major strengths. There has been incredible innovation during the Covid-19 pandemic, with acceleration of digital technologies, better ways of delivering healthcare and developments in vaccines and treatments that could be applied to many common diseases.

“We all have a stake in the post-Covid future and we all get to play a part in building it. That starts with a broad conversation about where we are going and what we want the future to look like. Hopefully that’s the conversation we will start at this event.”



......................


COVID-19: State of the art – DRAGON IMI project

29 April, 2021 Online

A full-day virtual event dedicated to COVID-19, where top level faculty will share the latest advances, data and best practices relating to SARS-CoV-2 and COVID-19.

“This event brings together world-leaders tackling COVD-19 and how different digital approaches to big data will help us to defeat the pandemic”

[bumpa33] 13/4/2021 14:16

I’m not seeing that today mesquida, quite the contrary...

[kingalf] 13/4/2021 10:00

Interesting article in the ft today
Drug discovery group C4X Discovery Holdings surged after announcing that its subsidiary had signed an exclusive worldwide licensing agreement with French pharma multinational Sanofi, worth up to €414m, to develop and commercialise an oral therapy for the treatment of inflammatory diseases.

“This licence is a validation of the C4XD business model, showing the significant value in early-stage programmes,” said Julie Simmonds, an analyst at Panmure Research, who reiterated her “buy” recommendation.

The deal shifted the cost of this particular project to Sanofi, “giving C4XD more cash to both invest in its existing programmes and also start to scale up development of the next generation of programmes”.

[mesquida] 12/4/2021 15:02

Still seems to be a lot of stock on offer, i am wondering if Richard Griffiths is going all the way down to Zero, no matter , once he is out we should see a good bounce, i remember JOG , Grifiths is not the Oracle !

[andymunchkin] 11/4/2021 12:47

moneymunch17 Feb '21 - 11:13 - 75 of 653
0 4 1
More likely, as I've suggested many times previously to much derision and gnashing of teeth....
———;——-
ThisCnt wasPumpng Ukog now@ .12p from £12. WachOit fer theDump ere

[bumpa33] 10/4/2021 20:27

interesting last line there mm, Sfx-01?

maybe :)

[bumpa33] 10/4/2021 20:26

Note that Chalmers says ‘controlled217; and not ‘eradicated217; in relation to Covid-19